ClinicalTrials.gg
Not yet recruitingNCT06589375SENSOUpdated Sep 19, 2024

Study of EEG and Nasal Stimulus in Olfactory Disorders

An interventional study of Sniffin'Sticks in Olfaction Disorders, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Neuroscent aims to analyze EEG signals induced by olfactory stimuli in individuals with normal and impaired olfactory functions, with a focus on patients with tinnitus. The study seeks to develop reliable diagnostic methods using EEG to differentiate between normosmic and hyposmic subjects during olfactory tests, potentially enhancing our understanding of the brain's response to olfactory stimuli. This 24-month interventional study with a device to be patented will involve 1000 participants and aims to establish more effective diagnostic and therapeutic tools for olfactory disorders

Read the detailed description

The Neuroscent project investigates the EEG signals elicited by olfactory stimuli in both normosmic individuals and those with olfactory disorders, with a focus on tinnitus patients. The primary objective is to utilize EEG analysis to identify and quantify brain wave responses during olfactory tests with Sniffin' Sticks, aiming to accurately differentiate between normosmic and hyposmic subjects. This research aims to enhance the diagnostic precision and understanding of the interplay between olfactory and auditory stimuli in the brain. The 24-month, interventional study with a device to be patented, co-financed by the Ministry of Health and Ministry of the Interior under the PNRR 2023, will recruit 1000 participants divided into four groups: normosmics (550), hyposmics (150), tinnitus patients with hyposmia (150), and tinnitus patients without hyposmia (150). Participants will undergo comprehensive olfactory assessments, including the Sniffin' Sticks test, and EEG recordings will be taken during olfactory stimulation to capture brain wave patterns. Advanced data analysis techniques, such as Random Forest algorithms and t-SNE dimensionality reduction, will be employed to classify and interpret the EEG signals, aiming to develop effective diagnostic and therapeutic tools for olfactory disorders, thereby improving clinical outcomes and quality of life for affected individuals.

02

Conditions studied

  • Olfaction Disorders

Keywords

  • Olfactory stimuli
  • EEG
  • Tinnitus
  • Olfactory disorders
  • Smell impairment
  • Olfactometry
  • Brain waves
03

In context

Olfaction Disorders

70 studies on the registry are indexed under Olfaction Disorders; 18 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 60 across 49 interventional studies indexed under Olfaction Disorders.

Browse Olfaction Disorders studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 952 studies on the registry; 541 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects over 18 years of age who have given consent for the collection of specified data, including medical history and personal information, for the purposes of project implementation and in accordance with the ethical standards of the institutions where the project will be conducted.

Exclusion criteria

Exclusion Criteria:

  • Previous fractures of the facial bones, particularly the ethmoid bone.
  • Active tumors of the brain or face, including tumors of the nose, paranasal sinuses, oral cavity, or nasopharynx.
  • Active nasal-sinus conditions, particularly radiologically proven sinusitis.
  • Mass in the pontocerebellar angle, especially schwannoma of the VIII nerve.
  • Patients with acute and chronic inflammatory diseases of the middle ear, otosclerosis, inner ear diseases (especially Meniere's disease), objective tinnitus, and tinnitus caused by middle ear pathologies and CPA tumors.
  • Neurodegenerative diseases (especially Alzheimer's and Parkinson's disease).
  • Known history of neuropsychiatric or cerebral disorders.
  • Use of psychotropic drugs or drugs active on the central nervous system.
  • Alcohol and drug abuse.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Active comparator
    Normosmic

    Participants in this group have normal olfactory function, as determined by the Sniffin' Sticks test. They will undergo EEG analysis while being exposed to various olfactory stimuli to establish baseline brain wave patterns for normal olfactory responses. (n=550)

    Diagnostic Test: Sniffin'Sticks

  • Active comparator
    Hyposmic

    Participants in this group have impaired olfactory function (hyposmia), confirmed through the Sniffin' Sticks test. They will undergo EEG analysis during olfactory stimulation to identify differences in brain wave patterns compared to normosmic individuals. (n=150)

    Diagnostic Test: Sniffin'Sticks

  • Active comparator
    Tinnitus Patients with Hyposmia

    This group includes participants who have both tinnitus and hyposmia. They will be subjected to EEG analysis during olfactory testing to investigate the interaction between olfactory and auditory disorders and how these conditions may influence brain wave responses. (n=150)

    Diagnostic Test: Sniffin'Sticks

  • Active comparator
    Tinnitus Patients without Hyposmia

    Participants in this group have tinnitus but normal olfactory function. They will undergo the same EEG and olfactory tests to explore the impact of tinnitus on brain wave patterns in the absence of olfactory disorders and to compare their responses with those of other groups. (n=150)

    Diagnostic Test: Sniffin'Sticks

Interventions

  • Diagnostic testSniffin'Sticks

    The Sniffin' Sticks test, a validated method to evaluate olfactory functions, utilizes pen-like devices to dispense scents for testing identification, discrimination, and detection of odors. In this study, participants' responses to various scents are recorded. EEG (Electroencephalography) captures electrical activity in the brain during exposure to these odors by using an EEG cap fitted with electrodes on the scalp. This allows for the monitoring of brain wave patterns in response to olfactory stimuli. Both the Sniffin' Sticks test and EEG recordings are conducted simultaneously, providing a dual assessment of behavioral reactions and brain activity to odors. The goal of the study is to compare brain wave patterns and olfactory function in normosmic (normal smell), hyposmic (reduced smell), and tinnitus patients with and without olfactory impairments, delivering comprehensive insights into the neural basis of olfactory perception.

    Also known as: EEG

06

What researchers measure

Primary outcomes

  1. Enrollment and data collection

    During this period, 1000 participants \> 18 y/o will be recruited and divided into four distinct groups: normosmics (550), hyposmics (150), tinnitus patients with hyposmia (150), and tinnitus patients without hyposmia (150). The primary outcome of the Neuroscent project is to assess the ability of EEG analysis to distinguish between normosmic and hyposmic participants during olfactory stimulation using the Sniffin' Sticks test.

    Time frame: 22 months

  2. EEG Parameters (in µV²)

    Alpha Power: Measured in microvolts squared (µV²), representing the magnitude of Alpha wave activity during olfactory stimulation. Theta Power: Measured in microvolts squared (µV²), representing the magnitude of Theta wave activity during olfactory stimulation. We will make use of the Fourier transform as well, which is inherently dimensionless. The data acquisition setup involves placing blindfolded participants in an isolated room and administering three randomized olfactory stimuli (pure olfactory, trigeminal, and olfactory-gustatory) while collecting EEG data. Sessions start and end with a 30-second resting state.

    Time frame: 22 months

  3. Behavioral/Performance Measures (Scores)

    Olfactory Threshold Scores (as per routinary diagnosis of olfactory performances): Derived from the Sniffin' Sticks test, these scores quantify participants' ability to detect odors, classifying them as normosmic or hyposmic. All the participants will undergo a complete olfactory assessment through the Sniffin' Sticks test. These are represented as numerical scores. The maximum score obtainable in the full Sniffin' Sticks test, which includes the three sub-tests (Threshold, Discrimination, Identification - TDI), is 48. This maximum score is achieved by summing the highest possible score from each of the three components: 16 for olfactory threshold (Threshold), 16 for olfactory discrimination (Discrimination), and 16 for olfactory identification (Identification).

    Time frame: 22 months

  4. Model Performance Metrics (Accuracy)

    Random Forest Model Classification Accuracy: The accuracy of the classification model used to distinguish between normosmic and hyposmic participants based on EEG data, usually expressed as a percentage or a value between 0 and 1.

    Time frame: 22 months

  5. Dimensionality Change Outputs (t-SNE)

    t-SNE Features: Although these don't have a specific unit, they represent the reduced dimensional data points used as features in the Random Forest model. These are typically dimensionless and used in the context of visualizing and improving model performance.

    Time frame: 22 months

Secondary outcomes

  1. Pure Tone Audiometry Test

    Pure Tone Audiometry (PTA), as per routinary diagnosis of Tinnitus: Measures hearing thresholds across frequencies, reported in decibels Hearing Level (dB HL) to determine the degree of hearing loss. The results are plotted on an audiogram, which shows the person's hearing threshold at different frequencies; a normal audiogram threshold is 0-20 dB HL between 250 and 8k Hz.

    Time frame: 22 months (Simultaneously with the primary outcome)

  2. Behavioral/Performance Measures (Scores)

    Tinnitus Handicap Inventory (THI): Scores the impact of tinnitus on a scale from 0 to 100, where a higher score indicates a worse impact of tinnitus.

    Time frame: 22 months (Simultaneously with the primary outcome)

  3. EEG Parameters

    EEG Data: Analyzed during exposure to olfactory stimuli (as per Primary Outcome), with features reduced via t-SNE and classified using a Random Forest algorithm.

    Time frame: 22 months (Simultaneously with the primary outcome)

  4. Model Performance Metrics

    Random Forest Model Classification Accuracy: Measures the accuracy of the model used to classify participants across the four groups. This is typically expressed as a percentage or a value between 0 and 1. Fleiss' Kappa Statistic: Used to evaluate the agreement of classification, reported as a kappa coefficient.

    Time frame: 22 months (Simultaneously with the primary outcome)

  5. Power Analysis and Post-hoc Analyses

    Power Analysis: Ensures the sample size is adequate to detect significant effects. This is typically expressed in terms of statistical power (e.g., 0.8 or 80%). Post-hoc Analyses: Conducted if significant differences are found, usually involving p-values or effect sizes.

    Time frame: 22 months (Simultaneously with the primary outcome)

  6. Auditory Brainstem Response (ABR)

    Auditory Brainstem Response (ABR) as per routinary diagnosis of Tinnitus: Assesses the auditory nerve and brainstem's response to sound stimuli by measuring electrical activity in the brain. Results are typically presented as waveforms, with particular focus on latency and amplitude of specific waves, measured in milliseconds (ms) and microvolts (µV) respectively, to evaluate neural pathways involved in hearing.

    Time frame: 22 months (Simultaneously with the primary outcome)

  7. Tympanometry

    Tympanometry, as per routinary diagnosis of Tinnitus: Evaluates middle ear function by measuring tympanic membrane mobility, with results reported in decapascals (daPa) and milliliters (mL). The pressure reading in tympanometry reflects the air pressure in the middle ear cavity. A normal tympanogram shows peak compliance when the pressure in the ear canal matches the pressure in the middle ear, indicating normal middle ear function. The two units of measurement, pressure and compliance, are plotted on a two-dimensional graph. Pressure (daPa) is plotted on the x-axis and compliance, measured in mL, is plotted on the y-axis in the two-dimensional graph

    Time frame: 22 months (Simultaneously with the primary outcome)

Other outcomes

  1. Predicting Odor Categories in Tinnitus and Non-Tinnitus Groups Using EEG and Machine Learning

    The final outcome will involve comparing olfactory perception across four participant groups (normosmic, normosmic with tinnitus, hyposmic, and hyposmic with tinnitus) using EEG features derived from Fourier analysis, reduced via t-SNE, and classified with a Random Forest algorithm. The model's accuracy in predicting odor categories (based on EEG data) will be evaluated using metrics such as accuracy, precision, recall, specificity, and F1 score. Fleiss' kappa statistic will assess agreement across groups, comparing the algorithm's predictions with the Sniffin' Sticks test results. Statistical power analysis ensures adequate sample sizes for reliable comparisons, with post-hoc analyses conducted if significant differences are detected.

    Time frame: 2 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06589375
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Aug 31, 2024 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Giuseppe Maulucci, Prof
Contact
giuseppe.maulucci@unicatt.it
+390630154265
Giulio Cesare Passali, Prof
Contact
giuliocesarepassali@policlinicogemelli.it
3331727194
Giulio Cesare Passali, Prof
study director · Fondazione Policlinico Universitario A. Gemelli, IRCCS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion